Immunogenicity of Ad26.COV2.S prime and two subsequent doses of mRNA SARS-CoV-2 vaccines in solid organ transplant recipients: A case series
Date:
07/13/2022
Citation:
Chang A, Mitchell J, Alejo JL, Chiang TPY, Abedon AT, Kim JD, Avery RK, Tobian AAR, Levan ML, Warren DS, Garonzik-Wang JM, Massie AB, Segev DL, Werbel WA. Immunogenicity of Ad26.COV2.S prime and two subsequent doses of mRNA SARS-CoV-2 vaccines in solid organ transplant recipients: A case series. Clin Transplant. 2022 Jul 13:e14772. doi: 10.1111/ctr.14772. Epub ahead of print. PMID: 35822545.
Abstract
Heterologous vaccination has been explored in small populations of solid organ transplant recipients (SOTRs), 1 , 2 , 3 , 4 yet 38% of participants had persistently suboptimal response indicating potential role for further vaccine doses. 1 The US CDC currently recommends immunocompromised adults who received an Ad26.COV2.S prime to receive one additional dose of SARS‐CoV‐2 mRNA vaccine, either BNT162b2 or mRNA‐1273, followed by two mRNA vaccine boosters, although the efficacy of this strategy in immunocompromised persons is not known. We evaluated serial antispike antibody responses and reactogenicity among SOTRs who received two doses of mRNA vaccine following Ad26.COV2.S prime.